Zydus Cadila receives USFDA approval for Carvedilol Tablets

Zydus Cadila has received an approval from the US FDA to market Carvedilol Tablets 3.125 mg, 6.25 mg, 12.5 mg and 25 mg, in the US market. The drug falls in the Cardiovascular segment. The sales of Carvedilol Tablets in the US market as per NDC Health is estimated at USD 1.24 bn.

Gaining a significant advantage, Zydus Pharmaceuticals (USA) Inc., launched its product on the very first day after receiving approval from the USFDA.

The group now has 27 approvals since the commencement of filing process in FY 2003-04. So far the group has filed 65 ANDAs and 55 DMFs."

The stock closed the day at Rs.325, up by Rs.0.80 or 0.25%. The stock hit an intraday high of Rs.326.85 and low of Rs.320.15. The total traded quantity was 14196 compared to 2 week average of 12848.

Source : Equity Bulls

Keywords